• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?

作者信息

Piantanida E, Bartalena L

机构信息

Department of Medicine and Surgery, Endocrine Unit, University of Insubria, ASST dei Sette Laghi, Ospedale di Circolo, Viale Borri, 57, Varese, Italy.

出版信息

J Endocrinol Invest. 2017 Aug;40(8):885-887. doi: 10.1007/s40618-017-0717-8. Epub 2017 Jun 20.

DOI:10.1007/s40618-017-0717-8
PMID:28634704
Abstract
摘要

相似文献

1
Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?替普罗单抗：治疗中重度活动性格雷夫斯眼眶病的新途径？
J Endocrinol Invest. 2017 Aug;40(8):885-887. doi: 10.1007/s40618-017-0717-8. Epub 2017 Jun 20.
2
Current and Emerging Treatment Strategies for Graves' Orbitopathy.格雷夫斯眼病的当前和新兴治疗策略。
Drugs. 2019 Feb;79(2):109-124. doi: 10.1007/s40265-018-1045-9.
3
Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?替普罗单抗治疗格雷夫斯眼病与耳毒性：问题从眼睛转移到耳朵了吗？
J Endocrinol Invest. 2022 Jul;45(7):1455-1457. doi: 10.1007/s40618-022-01791-w. Epub 2022 Apr 11.
4
Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.Graves 眼病活动期和中重度患者的治疗进展。
Lancet Diabetes Endocrinol. 2017 Feb;5(2):134-142. doi: 10.1016/S2213-8587(16)30046-8. Epub 2016 Jun 23.
5
Treatment of moderate-to-severe and active Graves' orbitopathy: a step forward from the OPTIC study.中重度及活动性格雷夫斯眼眶病的治疗：OPTIC研究的新进展
J Endocrinol Invest. 2020 Oct;43(10):1523-1525. doi: 10.1007/s40618-020-01223-7. Epub 2020 Apr 18.
6
Teprotumumab: First Approval.特罗替珠单抗：首次获批
Drugs. 2020 Apr;80(5):509-512. doi: 10.1007/s40265-020-01287-y.
7
Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.对特里·J·史密斯博士关于替普罗珠单抗与耳毒性的致编辑信的回复
J Endocrinol Invest. 2022 Aug;45(8):1603-1604. doi: 10.1007/s40618-022-01829-z. Epub 2022 May 28.
8
Treatment of moderate to severe orbitopathy: Current modalities and perspectives.中重度眼眶病的治疗：现有方法和前景。
Ann Endocrinol (Paris). 2021 Apr;82(2):92-98. doi: 10.1016/j.ando.2021.02.001. Epub 2021 Mar 4.
9
Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.特罗特鲁单抗在甲状腺相关眼病中的应用：治疗胰岛素样生长因子-I 受体抑制的原理。
J Neuroophthalmol. 2020 Mar;40(1):74-83. doi: 10.1097/WNO.0000000000000890.
10
Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.甲状腺相关眼病：特普西单抗作为一种有前途的医学治疗方法的出现。
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101383. doi: 10.1016/j.beem.2020.101383. Epub 2020 Jan 31.

引用本文的文献

1
Changes of mRNA expression underlying orbital adipogenesis in thyroid-associated orbitopathy.甲状腺相关眼病眶脂肪生成过程中mRNA表达的变化
Arch Med Sci. 2022 Oct 6;18(6):1708-1715. doi: 10.5114/aoms/153478. eCollection 2022.
2
Orbital Signaling in Graves' Orbitopathy.眼眶信号在格雷夫斯眼病中的作用。
Front Endocrinol (Lausanne). 2021 Nov 9;12:739994. doi: 10.3389/fendo.2021.739994. eCollection 2021.
3
Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects.输液中心特罗特单抗输注指南：知情同意、安全性和副作用管理。

本文引用的文献

1
Teprotumumab for Thyroid-Associated Ophthalmopathy.替普罗单抗治疗甲状腺相关性眼病
N Engl J Med. 2017 May 4;376(18):1748-1761. doi: 10.1056/NEJMoa1614949.
2
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?静脉注射糖皮质激素的早期反应能否预测中重度活动性格雷夫斯眼眶病患者的最终结局？
J Endocrinol Invest. 2017 May;40(5):547-553. doi: 10.1007/s40618-017-0608-z. Epub 2017 Feb 7.
3
Graves' Disease.格雷夫斯病
J Infus Nurs. 2021;44(6):331-338. doi: 10.1097/NAN.0000000000000446.
4
Oxidative Stress in Graves Disease and Graves Orbitopathy.格雷夫斯病和格雷夫斯眼眶病中的氧化应激
Eur Thyroid J. 2020 Dec;9(Suppl 1):40-50. doi: 10.1159/000509615. Epub 2020 Nov 20.
5
Teprotumumab: a disease modifying treatment for graves' orbitopathy.替普罗单抗：一种用于格雷夫斯眼病的疾病修饰疗法。
Thyroid Res. 2020 Jul 4;13:12. doi: 10.1186/s13044-020-00086-7. eCollection 2020.
6
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.格雷夫斯眼眶病患者的血清胆固醇水平与他汀类药物的使用：治疗的新起点
Front Endocrinol (Lausanne). 2020 Jan 22;10:933. doi: 10.3389/fendo.2019.00933. eCollection 2019.
7
Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.模仿格雷夫斯眼病的眼眶疾病：鉴别诊断中的长期挑战。
J Endocrinol Invest. 2020 Apr;43(4):401-411. doi: 10.1007/s40618-019-01141-3. Epub 2019 Nov 5.
8
Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?生物制剂是否会取代全身糖皮质激素成为甲状腺相关眼病的一线治疗方法？
Eur J Endocrinol. 2019 Nov;181(5):D27-D43. doi: 10.1530/EJE-19-0389.
9
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?糖皮质激素与其他免疫抑制药物联合使用能否减少中重度活动性格雷夫斯眼病患者的糖皮质激素累积剂量？
J Endocrinol Invest. 2019 Mar;42(3):351-352. doi: 10.1007/s40618-019-01015-8. Epub 2019 Feb 4.
10
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.格雷夫斯病和格雷夫斯眼病患者血清中胰岛素样生长因子-1 受体（IGF-1R）抗体。
J Endocrinol Invest. 2019 Apr;42(4):471-480. doi: 10.1007/s40618-018-0943-8. Epub 2018 Aug 21.
N Engl J Med. 2016 Oct 20;375(16):1552-1565. doi: 10.1056/NEJMra1510030.
4
MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials.内分泌疾病管理：利妥昔单抗治疗格雷夫斯眼病——来自随机对照试验的经验。
Eur J Endocrinol. 2017 Feb;176(2):R101-R109. doi: 10.1530/EJE-16-0552. Epub 2016 Oct 19.
5
Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.Graves 眼病活动期和中重度患者的治疗进展。
Lancet Diabetes Endocrinol. 2017 Feb;5(2):134-142. doi: 10.1016/S2213-8587(16)30046-8. Epub 2016 Jun 23.
6
Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any).格雷夫斯病所致甲状腺功能亢进症的管理：常见问题及解答（如有）。
J Endocrinol Invest. 2016 Oct;39(10):1105-14. doi: 10.1007/s40618-016-0505-x. Epub 2016 Jun 18.
7
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.2016年欧洲甲状腺协会/欧洲Graves眼病研究组Graves眼病管理指南
Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828. Epub 2016 Mar 2.
8
Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.利妥昔单抗B细胞靶向治疗对活动性中重度格雷夫斯眼眶病患者的疗效：一项随机对照研究。
J Clin Endocrinol Metab. 2015 Feb;100(2):422-31. doi: 10.1210/jc.2014-3014. Epub 2014 Dec 15.
9
Randomized controlled trial of rituximab in patients with Graves' orbitopathy.利妥昔单抗治疗格雷夫斯眼眶病患者的随机对照试验。
J Clin Endocrinol Metab. 2015 Feb;100(2):432-41. doi: 10.1210/jc.2014-2572. Epub 2014 Oct 24.
10
Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.三种不同累积剂量静脉注射甲基强的松龙治疗中重度和活动期格雷夫斯眼病的疗效和安全性。
J Clin Endocrinol Metab. 2012 Dec;97(12):4454-63. doi: 10.1210/jc.2012-2389. Epub 2012 Oct 4.